tbuckley/cabot-search huggingface dataset:
Demoralization and Quality of Life of Patients with Parkinson Disease
Authors: Boheng Zhu, Robert Kohn, Amar Patel, Brian B. Koo, Elan D. Louis, John M. de Figueiredo
Journal: Psychotherapy and Psychosomatics (2021)

Demoralization is quite prevalent in patients with Parkinson disease (PD). Unrecognized or untreated, demoralization may progress, at times, to demands for euthanasia and the desire for suicide. Typically, patients with PD do not complain of being "demoralized"; rather, they report disruptions in the quality of their lives. Hence, early identification of disruptions in health-related quality of life (HRQoL) specifically associated with demoralization may prompt earlier recognition and treatment. Published data on such associations, however, could not be found. Alleviation of demoralization in PD is likely to improve treatment outcomes. This research aimed at identifying the disruptions of HRQoL specifically associated with the demoralization of patients with PD. Consecutive general hospital outpatients with PD (n = 95) were assessed for: demoralization, with the Diagnostic Criteria for Psychosomatic Research Demoralization Scale (DCPR-D) and the Demoralization Scale (DS); depression, with the Patient Health Questionnaire-9 (PHQ-9); HRQoL, with the Parkinson Disease Questionnaire-Short Form (PDQ-8); sociodemographic variables; medical comorbidities; PD severity; and types of treatment. The prevalence of demoralization was 19%. Regression analyses showed that demoralization was significantly more likely to be experienced by participants who had difficulty with mobility and felt embarrassed in public due to having PD. Demoralization explained HRQoL over and above depression. Stigma and perceived difficulty with mobility are associated with demoralization of PD patients, and they may signal the need for psychotherapeutic and behavioral interventions to prevent the progression to helplessness, hopelessness, demands for euthanasia, and desire for suicide.
Transrectal endoscopic ultrasound in undiagnosed ascites: is it a peritoneal deposit?
Authors: Surinder S. Rana, Nikhil Bush, Rajesh Gupta
Journal: Endoscopy (2021)

A 38-year-old woman presented with abdominal distension of 2 months’ duration. Ultrasound and computed tomography (CT) scans revealed ascites. Ascitic fluid analysis revealed exudative fluid, with non-elevated fluid adenosine deaminase and amylase values. Cytological examination of the ascitic fluid did not reveal malignant cells. No fluorodeoxyglucose-avid lesions were observed on positron emission tomography (PET) scanning, and no abnormality was observed on either gastroscopy or colonoscopy. A peritoneal evaluation was performed by endoscopic ultrasound (EUS); however, no peritoneal lesion was observed on EUS performed from the stomach and duodenum. Rectal EUS was therefore subsequently performed, which revealed pelvic ascites, along with a well-defined echogenic nodular lesion adjacent to the parietal peritoneum of the lateral pelvic wall that, on initial evaluation, appeared to be a peritoneal deposit ([Fig. 1 a]). Careful anatomical evaluation revealed the lesion to be anterior to the internal iliac vessels. The lesion had a central echogenic area with a peripheral hypoechoic area, with cysts of varying sizes ([Fig. 1 b]).
A Neanderthal OAS1 isoform protects individuals of European ancestry against COVID-19 susceptibility and severity
Authors: Sirui Zhou, Guillaume Butler-Laporte, Tomoko Nakanishi, David R. Morrison, Jonathan Afilalo, Marc Afilalo, Laetitia Laurent, Maik Pietzner, Nicola Kerrison, Kaiqiong Zhao, Elsa Brunet-Ratnasingham, Danielle Henry, Nofar Kimchi, Zaman Afrasiabi, Nardin Rezk, Meriem Bouab, Louis Petitjean, Charlotte Guzman, Xiaoqing Xue, Chris Tselios, Branka Vulesevic, Olumide Adeleye, Tala Abdullah, Noor Almamlouk, Yiheng Chen, Michaël Chassé, Madeleine Durand, Clare Paterson, Johan Normark, Robert Frithiof, Miklós Lipcsey, Michael Hultström, Celia M. T. Greenwood, Hugo Zeberg, Claudia Langenberg, Elin Thysell, Michael Pollak, Vincent Mooser, Vincenzo Forgetta, Daniel E. Kaufmann, J. Brent Richards
Journal: Nature Medicine (2021)
How to beat night shift dread
Authors: Abi Rimmer
Journal: BMJ (2021)

How to beat night shift dreadIt's not unusual to feel anxious before starting a run of nights but there are ways to tackle this, Abi Rimmer hears Abi Rimmer Get a structured handoverArafat Mulla, specialty trainee year 4 in respiratory medicine, North West deanery, says, "Be in control and get to work early.Nothing is worse than running late for handover and having your heart racing before anything has even happened.
Underappreciated Roles of DNA Polymerase δ in Replication Stress Survival
Authors: Jeannette Fuchs, Anais Cheblal, Susan M. Gasser
Journal: Trends in Genetics (2021)

DNA polymerase δ is key to surviving replication stress, and is found in almost every oncogene-transformed mammalian cell line.Cancer-linked point mutations are found in POLD1, whereas POLD2 and POLD3 are found amplified in the vast majority of cancers.Hydroxyurea destabilizes Fe-S centers, which also compromises the stability of the DNA polymerase δ complex.Inhibitors of checkpoint kinases and reagents that compromise DNA polymerase δ activity may act synergistically to arrest growth in transformed cells. Recent structural analysis of Fe-S centers in replication proteins and insights into the structure and function of DNA polymerase δ (DNA Pol δ) subunits have shed light on the key role played by this polymerase at replication forks under stress. The sequencing of cancer genomes reveals multiple point mutations that compromise the activity of POLD1, the DNA Pol δ catalytic subunit, whereas the loci encoding the accessory subunits POLD2 and POLD3 are amplified in a very high proportion of human tumors. Consistently, DNA Pol δ is key for the survival of replication stress and is involved in multiple long-patch repair pathways. Synthetic lethality arises from compromising the function and availability of the noncatalytic subunits of DNA Pol δ under conditions of replication stress, opening the door to novel therapies. Recent structural analysis of Fe-S centers in replication proteins and insights into the structure and function of DNA polymerase δ (DNA Pol δ) subunits have shed light on the key role played by this polymerase at replication forks under stress. The sequencing of cancer genomes reveals multiple point mutations that compromise the activity of POLD1, the DNA Pol δ catalytic subunit, whereas the loci encoding the accessory subunits POLD2 and POLD3 are amplified in a very high proportion of human tumors. Consistently, DNA Pol δ is key for the survival of replication stress and is involved in multiple long-patch repair pathways. Synthetic lethality arises from compromising the function and availability of the noncatalytic subunits of DNA Pol δ under conditions of replication stress, opening the door to novel therapies.
Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study
Authors: Hannah Bower, Thomas Frisell, Daniela Di Giuseppe, Bénédicte Delcoigne, Gerd-Marie Ahlenius, Eva Baecklund, Katerina Chatzidionysiou, Nils Feltelius, Helena Forsblad-d'Elia, Alf Kastbom, Lars Klareskog, Elisabet Lindqvist, Ulf Lindström, Carl Turesson, Christopher Sjöwall, Johan Askling
Journal: Annals of the Rheumatic Diseases (2021)

To estimate absolute and relative risks for all-cause mortality and for severe COVID-19 in inflammatory joint diseases (IJDs) and with antirheumatic therapies.Through Swedish nationwide multiregister linkages, we selected all adult patients with rheumatoid arthritis (RA, n=53 455 in March 2020), other IJDs (here: spondyloarthropathies, psoriatic arthritis and juvenile idiopathic arthritis, n=57 112), their antirheumatic drug use, and individually matched population referents. We compared annual all-cause mortality March-September 2015 through 2020 within and across cohorts, and assessed absolute and relative risks for hospitalisation, admission to intensive care and death due to COVID-19 March-September 2020, using Cox regression.During March-September 2020, the absolute all-cause mortality in RA and in other IJDs was higher than 2015-2019, but relative risks versus the general population (around 2 and 1.5) remained similar during 2020 compared with 2015-2019. Among patients with IJD, the risks of hospitalisation (0.5% vs 0.3% in their population referents), admission to intensive care (0.04% vs 0.03%) and death (0.10% vs 0.07%) due to COVID-19 were low. Antirheumatic drugs were not associated with increased risk of serious COVID-19 outcomes, although for certain drugs, precision was limited.Risks of severe COVID-19-related outcomes were increased among patients with IJDs, but risk increases were also seen for non-COVID-19 morbidity. Overall absolute and excess risks are low and the level of risk increases are largely proportionate to those in the general population, and explained by comorbidities. With possible exceptions, antirheumatic drugs do not have a major impact on these risks.
Potential and pitfalls of whole transcriptome-based immunogenetic marker identification in acute lymphoblastic leukemia; a EuroMRD and EuroClonality-NGS Working Group study
Authors: Vincent H. J. van der Velden, Monika Brüggemann, Giovanni Cazzaniga, Blanca Scheijen, Bastiaan Tops, Jan Trka, Karol Pal, Sonja Hänzelmann, Grazia Fazio, Simona Songia, Anton W. Langerak, Nikos Darzentas
Journal: Leukemia (2021)

Identification of immunoglobulin (IG) and T-cell receptor (TR) gene rearrangements in acute lymphoblastic leukemia (ALL) patients at initial presentation is crucial for monitoring of minimal residual disease (MRD) during subsequent follow-up and thereby for appropriate risk-group stratification.In a diagnostic setting, IG/TR gene rearrangements are generally identified using DNA-based PCR analysis, followed by classical Sanger sequencing or next generation sequencing (NGS) [1,2].Nowadays, whole transcriptome RNA sequencing (RNAseq) is frequently used to identify fusion genes and to assign patients into distinct molecular subgroups according to WHO 2016 classification, or for protocol-based clinical decisions [3].Hence, it would be beneficial if RNAseq data could also be used for the identification of IG/TR gene rearrangements pertaining to the leukemic clone.Recently, Yeoh and colleagues reported on the use of RNAseq data for identification of IG heavy chain (IGH) gene rearrangements, which was successful in approximately 90% of B-ALL patients [4].Almost two-thirds of clonal IGH rearrangements were unproductive, whereas the vast majority (>98%) of background rearrangements were productive.Even though these data are promising, they are also incomplete since other IG/TR loci were not evaluated.Furthermore, these data underline that caution is warranted in the analysis of RNAseq data for IG/TR marker screening in ALL (and in other lymphoproliferative disorders requiring multiple RNA/DNA analyses): [5, 6] applying computational methods that only focus on productive rearrangements (e.g., like for most repertoire analyses) will clearly result in incomplete interpretation of IG/TR data for marker identification.Within the EuroClonality-NGS Working Group and EuroMRD, we have developed, validated, and published assays for IG/TR DNA amplicon ('DNAamp' hereafter) and DNA capture-based analysis of relevant samples [1,7,8].In line with these recent efforts, we decided to explore the possibilities and limitations of extracting data on IG/TR gene rearrangements from RNAseq data.Here we report on a complete but preliminary analysis of all IG/TR loci from RNAseq data, using DNAamp data as benchmark.RNAseq data from 165 ALL patients at time of diagnosis were obtained using Illumina TruSeq Library Prep or Universal RNAseq kit (Nugen, Tecan) and sequenced by Illumina Next-Seq or Novaseq (2 × 75 bp).DNAamp IG/TR
Association between county jail incarceration and cause-specific county mortality in the USA, 1987–2017: a retrospective, longitudinal study
Authors: Sandhya Kajeepeta, Pia M Mauro, Katherine M Keyes, Abdulrahman M El-Sayed, Caroline G Rutherford, Seth J Prins
Journal: The Lancet Public Health (2021)

Mass incarceration has collateral consequences for community health, which are reflected in county-level health indicators, including county mortality rates. County jail incarceration rates are associated with all-cause mortality rates in the USA. We assessed the causes of death that drive the relationship between county-level jail incarceration and mortality.
Ace Inhibitors, Angiotensin Receptor Blockers, and Outcomes in Hospitalized Patients With Severe Covid-19 Pneumonia
Authors: P. Grewal, J. Yoo, A. Papamanoli, A. Mojahedi, S. Dhaliwal, J. Nakamura, J. Abata, J. Robin, J. Fung, J. Hotelling, S. Rawal, N. Karkala, S. T. Tsui, A. Coritsidis, L. Marcos, M. E. Bloom, H. Skopicki, A. P. Kalogeropoulos
Journal: Circulation (2020)
The effect of a microbial ecosystem therapeutic (MET-2) on recurrent Clostridioides difficile infection: a phase 1, open-label, single-group trial
Authors: Dina Kao, Karen Wong, Rose Franz, Kyla Cochrane, Keith Sherriff, Linda Chui, Colin Lloyd, Brandi Roach, Anthony D Bai, Elaine O Petrof, Emma Allen-Vercoe
Journal: The Lancet. Gastroenterology & hepatology (2021)
Endoscopic surgery compared with intensity-modulated radiotherapy in resectable locally recurrent nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial
Authors: You-Ping Liu, Yi-Hui Wen, Jun Tang, Yi Wei, Rui You, Xiao-Lin Zhu, Jian Li, Lin Chen, Li Ling, Ning Zhang, Xiong Zou, Yi-Jun Hua, You-Mou Chen, Lei Chen, Li-Xia Lu, Ming-Yuan Chen, Wei-Ping Wen
Journal: The Lancet Oncology (2021)
Risks of post-colonoscopic polypectomy bleeding and thromboembolism with warfarin and direct oral anticoagulants: a population-based analysis
Authors: Louis HS Lau, Cosmos LT Guo, Terry CF Yip, Joyce WY Mak, Sunny H Wong, Kelvin LY Lam, Grace LH Wong, Siew C Ng, Francis KL Chan
Journal: Gut (2021)

There were limited data on the risk of post-polypectomy bleeding (PPB) in patients on direct oral anticoagulants (DOAC). We aimed to evaluate the PPB and thromboembolic risks among DOAC and warfarin users in a population-based cohort.We performed a territory-wide retrospective cohort study involving patients in Hong Kong from 2012 to 2020. Patients who received an oral anticoagulant and had undergone colonoscopy with polypectomy were identified. Propensity-score models with inverse probability of treatment weighting were developed for the warfarin-DOAC and between-DOAC comparisons. The primary outcome was clinically significant delayed PPB, defined as repeat colonoscopy requiring haemostasis within 30 days. The secondary outcomes were 30-day blood transfusion requirement and new thromboembolic event.Apixaban was associated with lower PPB risk than warfarin (adjusted HR (aHR) 0.39, 95% CI 0.24 to 0.63, p<0.001). Dabigatran (aHR 2.23, 95% CI 1.04 to 4.77, adjusted p (ap)=0.035) and rivaroxaban (aHR 2.72, 95% CI 1.35 to 5.48, ap=0.002) were associated with higher PPB risk than apixaban. In subgroup analysis, apixaban was associated with lower PPB risk in patients aged ≥70 years and patients with right-sided colonic polyps.For thromboembolic events, apixaban was associated with lower risk than warfarin (aHR 0.22, 95% CI 0.11 to 0.45, p<0.001). Dabigatran (aHR 2.60, 95% CI 1.06 to 6.41, ap=0.033) and rivaroxaban (aHR 2.96, 95% CI 1.19 to 7.37, ap =0.013) were associated with higher thromboembolic risk than apixaban.Apixaban was associated with a significantly lower risk of PPB and thromboembolism than warfarin, dabigatran and rivaroxaban, particularly in older patients with right-sided polyps.
Reactive astrocyte nomenclature, definitions, and future directions
Authors: Carole Escartin, Elena Galea, András Lakatos, James P. O’Callaghan, Gabor C. Petzold, Alberto Serrano-Pozo, Christian Steinhäuser, Andrea Volterra, Giorgio Carmignoto, Amit Agarwal, Nicola J. Allen, Alfonso Araque, Luis Barbeito, Ari Barzilai, Dwight E. Bergles, Gilles Bonvento, Arthur M. Butt, Wei-Ting Chen, Martine Cohen-Salmon, Colm Cunningham, Benjamin Deneen, Bart De Strooper, Blanca Díaz-Castro, Cinthia Farina, Marc Freeman, Vittorio Gallo, James E. Goldman, Steven A. Goldman, Magdalena Götz, Antonia Gutiérrez, Philip G. Haydon, Dieter H. Heiland, Elly M. Hol, Matthew G. Holt, Masamitsu Iino, Ksenia V. Kastanenka, Helmut Kettenmann, Baljit S. Khakh, Schuichi Koizumi, C. Justin Lee, Shane A. Liddelow, Brian A. MacVicar, Pierre Magistretti, Albee Messing, Anusha Mishra, Anna V. Molofsky, Keith K. Murai, Christopher M. Norris, Seiji Okada, Stéphane H. R. Oliet, João F. Oliveira, Aude Panatier, Vladimir Parpura, Marcela Pekna, Milos Pekny, Luc Pellerin, Gertrudis Perea, Beatriz G. Pérez-Nievas, Frank W. Pfrieger, Kira E. Poskanzer, Francisco J. Quintana, Richard M. Ransohoff, Miriam Riquelme-Perez, Stefanie Robel, Christine R. Rose, Jeffrey D. Rothstein, Nathalie Rouach, David H. Rowitch, Alexey Semyanov, Swetlana Sirko, Harald Sontheimer, Raymond A. Swanson, Javier Vitorica, Ina-Beate Wanner, Levi B. Wood, Jiaqian Wu, Binhai Zheng, Eduardo R. Zimmer, Robert Zorec, Michael V. Sofroniew, Alexei Verkhratsky
Journal: Nature Neuroscience (2021)
MicroRNA‐29s suppressed both soluble ST2 release and IFNAR1 expression in human bronchial epithelial cells
Authors: Arisa Igarashi, Kenji Matsumoto, Akio Matsuda
Journal: Allergy (2021)

Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Risk of Spinal Hematoma After Lumbar Puncture
Authors: Tao Xu, You Wang, Yangmei Chen
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Gastrointestinal motility disorders in neurologic disease
Authors: Michael Camilleri
Journal: Journal of Clinical Investigation (2021)

The extrinsic and autonomic nervous system intricately controls the major functions of the gastrointestinal tract through the enteric nervous system; these include motor, secretory, sensory, storage, and excretory functions. Disorders of the nervous system affecting gastrointestinal tract function manifest primarily as abnormalities in motor (rather than secretory) functions. Common gastrointestinal symptoms in neurologic disorders include sialorrhea, dysphagia, gastroparesis, intestinal pseudo-obstruction, constipation, diarrhea, and fecal incontinence. Diseases of the entire neural axis ranging from the cerebral hemispheres to the peripheral autonomic nerves can result in gastrointestinal motility disorders. The most common neurologic diseases affecting gastrointestinal function are stroke, parkinsonism, multiple sclerosis, and diabetic neuropathy. Diagnosis involves identification of the neurologic disease and its distribution, and documentation of segmental gut dysfunction, typically using noninvasive imaging, transit measurements, or intraluminal measurements of pressure activity and coordination of motility. Apart from treatment of the underlying neurologic disease, management focuses on restoration of normal hydration and nutrition and pharmacologic treatment of the gut neuromuscular disorder.
Abstract 10727: Need for Hemodynamic Support in High-risk Patients Undergoing Vt Ablation With Substrate-based Approach
Authors: Sanghamitra Mohanty, Chintan G Trivedi, Domenico G Della Rocca, Mohammed Bassiouny, Ugur Canpolat, Carola Gianni, Bryan MacDonald, Javier Sanchez, Joe Gallinghouse, John D Burkhardt, Rodney P Horton, Amin Al-ahmad, Jorge Romero, Luigi Di Biase, Andrea Natale
Journal: Circulation (2019)

Background: Hemodynamically unstable VT is seen in about 50-80% of patients with structural heart disease. Use of anesthesia, induction of VT and fluid overload during catheter ablation can worsen ...
Neural state space alignment for magnitude generalization in humans and recurrent networks
Authors: Hannah Sheahan, Fabrice Luyckx, Stephanie Nelli, Clemens Teupe, Christopher Summerfield
Journal: Neuron (2021)

<h2>Summary</h2> A prerequisite for intelligent behavior is to understand how stimuli are related and to generalize this knowledge across contexts. Generalization can be challenging when relational patterns are shared across contexts but exist on different physical scales. Here, we studied neural representations in humans and recurrent neural networks performing a magnitude comparison task, for which it was advantageous to generalize concepts of "more" or "less" between contexts. Using multivariate analysis of human brain signals and of neural network hidden unit activity, we observed that both systems developed parallel neural "number lines" for each context. In both model systems, these number state spaces were aligned in a way that explicitly facilitated generalization of relational concepts (more and less). These findings suggest a previously overlooked role for neural normalization in supporting transfer of a simple form of abstract relational knowledge (magnitude) in humans and machine learning systems.
Corrigendum to “Functional and Biochemical Consequences of Disease Variants in Neurotransmitter Transporters: A Special Emphasis on Folding and Trafficking Deficits” [Pharmacology &amp; Therapeutics 222 (2021) 107785]
Authors: Shreyas Bhat, Ali El-Kasaby, Florian P. Fischer, Michael Freissmuth, Sonja Sucic
Journal: Pharmacology & Therapeutics (2021)
Immunogenicity of CAR T cells in cancer therapy
Authors: Dimitrios L. Wagner, Enrico Fritsche, Michael A. Pulsipher, Nabil Ahmed, Mohamad Hamieh, Meenakshi Hegde, Marco Ruella, Barbara Savoldo, Nirali N. Shah, Cameron J. Turtle, Alan S. Wayne, Mohamed Abou-el-Enein
Journal: Nature Reviews Clinical Oncology (2021)
Upregulation of AXL and β-catenin in chronic lymphocytic leukemia cells cultured with bone marrow stroma cells is associated with enhanced drug resistance
Authors: Sutapa Sinha, Charla R. Secreto, Justin C. Boysen, Connie Lesnick, Zhiquan Wang, Wei Ding, Timothy G. Call, Saad J. Kenderian, Sameer A. Parikh, Steven L. Warner, David J. Bearss, Asish K. Ghosh, Neil E. Kay
Journal: Blood Cancer Journal (2021)